Susceptibility of Pseudomonas aeruginosa of various pyocin types to the newly synthesized ampicillin derivative, N-(6,7-difluoroquinolonyl)-ampicillin

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue 3, 1997, Pages 325-330

  Chen, C H ^a   Tsou, T L ^b   Chiang, H Y ^b   Lee, S H ^b   Lee, F ^b   Lee, J H ^a   Wang, T M ^b   Liu, Y T ^b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AMPICILLIN DERIVATIVE; ANTIBIOTIC AGENT; ENOXACIN; N (6,7 DIFLUOROQUINOLONYL)AMPICILLIN; NALIDIXIC ACID; NORFLOXACIN; PYOCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; NONHUMAN; PSEUDOMONAS AERUGINOSA; STRAIN DIFFERENCE; TAIWAN;

AMPICILLIN; AMPICILLIN RESISTANCE; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; ENOXACIN; MICROBIAL SENSITIVITY TESTS; NALIDIXIC ACID; NORFLOXACIN; PENICILLINS; PSEUDOMONAS AERUGINOSA; PYOCINS;

EID: 0030988019     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.3.325     Document Type: Article

References (27)

1. Bodey, G. P., Bolivar, R., Fainstein, V. & Jadeja, L. (1983). Infections caused by Pseudomonas aeruginosa. Reviews of Infectious Diseases 5, 279-313.
2. Fyfe, J. A. M., Harris, Q. & Govan, J. R. W. (1984). Revised pyocin typing method for Pseudomonas aeruginosa. Journal of Clinical Microbiology 20, 47-50.
3. Sheretz, R. J. & Sarubbi, F. A. (1983). A three-year study of nosocomial infections associated with Pseudomonas aeruginosa. Journal of Clinical Microbiology 18, 160-4.
4. Ojeniyi, B., Petersen, U. S. & Hoiby, N. (1993). Comparison of genome fingerprinting with conventional typing methods used on Pseudomonas aeruginosa isolates from cystic fibrosis patients. APMIS 101, 168-75.
5. Sader, H. S., Pignatari, A. C., Lerne, I. L., Burattini, M. N., Tancresi, R., Mollis, R. J. et al. (1993). Epidemiologic typing of multiply drug-resistant Pseudomonas aeruginosa isolated from an outbreak in an intensive care unit. Diagnostic Microbiology and Infectious Disease 17, 13-8.
6. Gillies, R. R. & Govan, J. R. W. (1966). Typing of Pseudomonas pyocyanea by pyocine production. Journal of Pathology and Bacteriology 91, 339-45.
7. Williams, R. J. & Govan, J. R. W. (1973). Pyocine typing of mucoid strains of Pseudomonas aeruginosa isolated from children with cystic fibrosis. Journal of Medical Microbiology, 6, 409-12.
8. Poh, C. L., Yap, E. H., Tay, L. & Bergan, T. (1988). Plasmid profiles compared with serotyping and pyocin typing for epidemiclogical surveillance of Pseudomonas aeruginosa. Journal of Medical Microbiology 25, 109-14.
9. Govan, J. R. W. & Gillies, R. R. (1969). Further studies in the pyocine typing of Pseudomonas pyocyanea. Journal of Medical Microbiology 2, 17-25.
10. Sarma, N. V., Shriniwas & Srinivas, R. V. (1980). Production of S and R pyocins by Pseudomonas aeruginosa - a preliminary study. Indian Journal of Medical Research 71, 36-8.
11. Fegan, M., Francis, P., Hayward, A. C. & Fuerst, J. A. (1991). Heterogeneity, persistance, and distribution of Pseudomonas aeruginosa genotypes in cystic fibrosis patients. Journal of Clinical Microbiology 29, 2151-7.
12. Koga, H., Itoh, A., Murayama, S., Suzue, S. & Irikura, T. (1980). Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids. Journal of Medicinal Chemistry 23, 1358-63.
13. Govan, J. R. W. (1978). Pyocin typing of Pseudomonas aeruginosa. In Methods in Microbiology, Vol. 10 (Bergan, T. & Norris, J. R., Eds), pp. 61-91. Academic Press, London.
14. Tagg, J. R. & Mushin, R. (1971). Epidemiology of Pseudomonas aeruginosa infection in hospitals. 1. Pyocine typing of Ps. aeruginosa. Medical Journal of Australia i, 847-52.
15. Kuroda, K. & Kageyama, M. (1979). Biochemical properties of a new flexuous bacteriocin, pyocin F1, produced by Pseudomonas aeruginosa. Journal of Biochemistry 85, 7-19.
16. Tredgett, M. W., Doherty, C. & Govan, J. R. W. (1990). Incidence of common pyocin types of Pseudomonas aeruginosa from patients with cystic fibrosis and chronic airways diseases. Journal of Medical Microbiology 32, 169-72.
17. Matsumoto, T., Miyamoto, T., Minamida, A., Nishimura, Y., Egawa, H. & Nishimura, H. (1984). Pyridonecarboxylic acids as antibacterial agents. 2. Synthesis and structure-activity relationships of 1,6,7-trisubstituted 1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids, including enoxacin, a new antibacterial agent. Journal of Medicinal Chemistry 27, 292-301.
18. Kresken, M. & Wiedemann, B. (1988). Development of resistance to nalidixic acid and the fluoroquinolones after the introduction to norfloxacin and ofloxacin. Antimicrobial Agents and Chemotherapy 32, 1285-8.
19. Shen, L. L. & Pernet, A. G. (1985). Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drug is DNA. Proceedings of the National Academy of Sciences of the United States of America 82, 307-11.
20. Wolfson, J. S. & Hooper, D. C. (1985). The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrobial Agents and Chemotherapy 28, 581-6.
21. Hooper, D. C. & Wolfson, J. S. (1991). Fluoroquinolone antimicrobial agents. New England Journal of Medicine 324, 384-94.
22. Tenney, J. H., Maack, R. W. & Chippendale, G. R. (1983). Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar. Antimicrobial Agents and Chemotherapy 23, 188-9.
23. Stamey, T. A., Nemoy, N. J. & Higgins, M. (1969). The clinical use of nalidixic acid. A review and some observations. Investigative Urology 6, 582-92.
24. Neu, H. C. (1983). The role of Pseudomonas aeruginosa in infections. Journal of Antimicrobial Chemotherapy 11, Suppl. B, 1-13.
25. Ishino, F. & Matsuhashi, M. (1981). Peptidoglycan synthetic enzyme activities of a highly purified penicillin-binding protein 3 in Escherichia coli, a septum-forming reaction sequence. Biochemical and Biophysical Research Communications 101, 905-11.
26. Linie, J. W. & Mount, D. W. (1982). The SOS regulatory system of Escherichia coli. Cell 29, 11-22.
27. Georgopapadakou, N. H. & Bertasso, A. (1993). Mechanisms of action of cephalosporin 3′-quinolone esters, carbamates, and tertiary amines in Escherichia coli. Antimicrobial Agents and Chemotherapy 37, 559-65.